GB202117609D0 - 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia - Google Patents

2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia

Info

Publication number
GB202117609D0
GB202117609D0 GBGB2117609.4A GB202117609A GB202117609D0 GB 202117609 D0 GB202117609 D0 GB 202117609D0 GB 202117609 A GB202117609 A GB 202117609A GB 202117609 D0 GB202117609 D0 GB 202117609D0
Authority
GB
United Kingdom
Prior art keywords
oxothiazole
compositions
treatment
acute lymphoblastic
cell acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2117609.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AB
Original Assignee
Coegin Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coegin Pharma AB filed Critical Coegin Pharma AB
Priority to GBGB2117609.4A priority Critical patent/GB202117609D0/en
Publication of GB202117609D0 publication Critical patent/GB202117609D0/en
Priority to PCT/EP2022/084623 priority patent/WO2023104809A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
GBGB2117609.4A 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia Ceased GB202117609D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2117609.4A GB202117609D0 (en) 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
PCT/EP2022/084623 WO2023104809A2 (en) 2021-12-06 2022-12-06 2-oxothiazole compositions for treatment of t-cell acute lymphoblastic leukaemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2117609.4A GB202117609D0 (en) 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia

Publications (1)

Publication Number Publication Date
GB202117609D0 true GB202117609D0 (en) 2022-01-19

Family

ID=80080911

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2117609.4A Ceased GB202117609D0 (en) 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia

Country Status (2)

Country Link
GB (1) GB202117609D0 (en)
WO (1) WO2023104809A2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101997163B1 (en) 2009-10-02 2019-07-08 아벡신 에이에스 Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
KR102268357B1 (en) 2013-01-29 2021-06-23 아벡신 에이에스 Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors
GB201806663D0 (en) 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
GB201906864D0 (en) 2019-05-15 2019-06-26 Avexxin As Combination therapy

Also Published As

Publication number Publication date
WO2023104809A3 (en) 2023-07-20
WO2023104809A2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
EP4119156A4 (en) Medicament for treatment and/or prevention of cancer
IL300067A (en) Compositions and methods for treatment of cancers
IL308195A (en) Ras inhibitors for the treatment of cancer
IL308221A (en) Compositions and methods for the treatment of depression
EP4110344A4 (en) Use of thyromimetics for the treatment of cancer
EP4138852A4 (en) Compositions and methods for the treatment of pain
EP4110369A4 (en) Methods of treatment and related compositions
GB202117609D0 (en) 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
EP4096653A4 (en) Compositions for the treatment of angiolipoma
EP4114864A4 (en) Compositions and methods for treatment of cancer
GB202316745D0 (en) Cd19car t-cell treatment of relapsed/regractory b-cell acute lymphoblastic leukaemia
EP4119157A4 (en) Medicament for treatment and/or prevention of cancer
EP4119159A4 (en) Medicament for treatment and/or prevention of cancer
EP4119158A4 (en) Medicament for treatment and/or prevention of cancer
EP4119160A4 (en) Medicament for treatment and/or prevention of cancer
EP4114411A4 (en) Compositions and methods for the treatment of pancreatic cancer
EP4053127A4 (en) Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same
GB202318794D0 (en) Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
GB202308063D0 (en) CD19CAR T-cell treatment of relapsed/refractory B-cell acute lymphoblastic leukaemia
EP3911306C0 (en) Petrolatum-based phmb compositions and methods of treatment for onychomycosis
EP4125920A4 (en) Methods and compositions for treatment of covid-19
KR102412352B9 (en) ERR- Pharmaceutical Composition for Treatment of Leukemia Comprising ERR- Antagonist
GB202109830D0 (en) VCP inhibitors and uses thereof for treatment
GB202016159D0 (en) Compound, compositions and methods for the treatment of pain
GB202315695D0 (en) TReatment of cariomyopathy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)